View in EDS HTML Full Text PDF Full Text

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.

Saved in:
Bibliographic Details
Title: Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Authors: Moy B; Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA. bmoy@mgh.harvard.edu., Oliveira M; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain., Saura C; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain., Gradishar W; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea., Brufsky A; Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA., Hurvitz SA; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA., Ryvo L; Assuta Ashdod Medical Center, Ashdod, Israel., Fagnani D; Azienda Socio-Sanitaria Territoriale Di Vimercate, Vimercate, Italy., Kalmadi S; Ironwood Cancer and Research Center, Chandler, AZ, USA., Silverman P; University Hospitals Cleveland Medical Center, Cleveland, OH, USA., Delaloge S; Gustave Roussy, Villejuif, France., Alarcon J; Servicio de Oncologia, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Kwong A; Department of Surgery, Queen Mary Hospital, Hong Kong, Hong Kong., Lee KS; National Cancer Center, Gyeonggi-do, Republic of Korea., Ang PCS; Gleneagles Medical Centre, Singapore, Singapore., Ow SGW; National University Cancer Institute, Singapore, Singapore., Chu SC; Hualien Tzu Chi Medical Center, Hualien, Taiwan., Bryce R; Puma Biotechnology Inc., Los Angeles, CA, USA., Keyvanjah K; Puma Biotechnology Inc., Los Angeles, CA, USA., Bebchuk J; Puma Biotechnology Inc., Los Angeles, CA, USA., Zhang B; Puma Biotechnology Inc., Los Angeles, CA, USA., Oestreicher N; Puma Biotechnology Inc., Los Angeles, CA, USA., Bose R; Washington University School of Medicine, St. Louis, MO, USA., Chan N; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
Source: Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Jul; Vol. 188 (2), pp. 449-458. Date of Electronic Publication: 2021 Apr 28.
Publication Type: Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 33909203
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Moy+B%22">Moy B</searchLink>; Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA, 02114, USA. bmoy@mgh.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Oliveira+M%22">Oliveira M</searchLink>; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Saura+C%22">Saura C</searchLink>; Vall D'Hebron University Hospital, Vall D'Hebron Institute of Oncology, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Gradishar+W%22">Gradishar W</searchLink>; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Kim+SB%22">Kim SB</searchLink>; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Brufsky+A%22">Brufsky A</searchLink>; Magee-Womens Hospital of UPMC, Pittsburgh, PA, USA.<br /><searchLink fieldCode="AU" term="%22Hurvitz+SA%22">Hurvitz SA</searchLink>; University of California Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Ryvo+L%22">Ryvo L</searchLink>; Assuta Ashdod Medical Center, Ashdod, Israel.<br /><searchLink fieldCode="AU" term="%22Fagnani+D%22">Fagnani D</searchLink>; Azienda Socio-Sanitaria Territoriale Di Vimercate, Vimercate, Italy.<br /><searchLink fieldCode="AU" term="%22Kalmadi+S%22">Kalmadi S</searchLink>; Ironwood Cancer and Research Center, Chandler, AZ, USA.<br /><searchLink fieldCode="AU" term="%22Silverman+P%22">Silverman P</searchLink>; University Hospitals Cleveland Medical Center, Cleveland, OH, USA.<br /><searchLink fieldCode="AU" term="%22Delaloge+S%22">Delaloge S</searchLink>; Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Alarcon+J%22">Alarcon J</searchLink>; Servicio de Oncologia, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.<br /><searchLink fieldCode="AU" term="%22Kwong+A%22">Kwong A</searchLink>; Department of Surgery, Queen Mary Hospital, Hong Kong, Hong Kong.<br /><searchLink fieldCode="AU" term="%22Lee+KS%22">Lee KS</searchLink>; National Cancer Center, Gyeonggi-do, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Ang+PCS%22">Ang PCS</searchLink>; Gleneagles Medical Centre, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Ow+SGW%22">Ow SGW</searchLink>; National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Chu+SC%22">Chu SC</searchLink>; Hualien Tzu Chi Medical Center, Hualien, Taiwan.<br /><searchLink fieldCode="AU" term="%22Bryce+R%22">Bryce R</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Keyvanjah+K%22">Keyvanjah K</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Bebchuk+J%22">Bebchuk J</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Zhang+B%22">Zhang B</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Oestreicher+N%22">Oestreicher N</searchLink>; Puma Biotechnology Inc., Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Bose+R%22">Bose R</searchLink>; Washington University School of Medicine, St. Louis, MO, USA.<br /><searchLink fieldCode="AU" term="%22Chan+N%22">Chan N</searchLink>; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228111104%22">Breast cancer research and treatment</searchLink> [Breast Cancer Res Treat] 2021 Jul; Vol. 188 (2), pp. 449-458. <i>Date of Electronic Publication: </i>2021 Apr 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Kluwer+Academic%22">Kluwer Academic </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>8111104 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-7217 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676806%22">01676806 </searchLink><i>NLM ISO Abbreviation: </i>Breast Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33909203
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10549-021-06217-4
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 449
    Titles:
      – TitleFull: Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Moy B
      – PersonEntity:
          Name:
            NameFull: Oliveira M
      – PersonEntity:
          Name:
            NameFull: Saura C
      – PersonEntity:
          Name:
            NameFull: Gradishar W
      – PersonEntity:
          Name:
            NameFull: Kim SB
      – PersonEntity:
          Name:
            NameFull: Brufsky A
      – PersonEntity:
          Name:
            NameFull: Hurvitz SA
      – PersonEntity:
          Name:
            NameFull: Ryvo L
      – PersonEntity:
          Name:
            NameFull: Fagnani D
      – PersonEntity:
          Name:
            NameFull: Kalmadi S
      – PersonEntity:
          Name:
            NameFull: Silverman P
      – PersonEntity:
          Name:
            NameFull: Delaloge S
      – PersonEntity:
          Name:
            NameFull: Alarcon J
      – PersonEntity:
          Name:
            NameFull: Kwong A
      – PersonEntity:
          Name:
            NameFull: Lee KS
      – PersonEntity:
          Name:
            NameFull: Ang PCS
      – PersonEntity:
          Name:
            NameFull: Ow SGW
      – PersonEntity:
          Name:
            NameFull: Chu SC
      – PersonEntity:
          Name:
            NameFull: Bryce R
      – PersonEntity:
          Name:
            NameFull: Keyvanjah K
      – PersonEntity:
          Name:
            NameFull: Bebchuk J
      – PersonEntity:
          Name:
            NameFull: Zhang B
      – PersonEntity:
          Name:
            NameFull: Oestreicher N
      – PersonEntity:
          Name:
            NameFull: Bose R
      – PersonEntity:
          Name:
            NameFull: Chan N
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2021 Jul
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1573-7217
          Numbering:
            – Type: volume
              Value: 188
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Breast cancer research and treatment
              Type: main
ResultId 1